India – Most Economical Destination for Conducting Global Clinical TrialsBy: Shushmul Maheshwari
|
India – Most Economical Destination for Conducting Global Clinical Trials
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
Developing a new drug is getting costlier, with our research, “Booming Clinical Trials Market in India”, estimating the cost of developing a new drug at nearly US$ 1200 in 2008, with nearly half of the cost being spent on clinical trials (phase-I to phase-IV). As a result, all major drug companies and CROs are outsourcing their clinical trials to offshore destinations to curb their surging costs.
According to our analysis, India is one of the most economical destinations for conducting global clinical trials. Companies can save a substantial amount in India on both staff and utilities. For instance, the salary of a clinical research associate is only 13% of that in the US and 17% and 19% as that in the UK and Germany respectively. Similarly, the cost of a biostatistician in India is only 15%, 18% and 17% as that in the US, UK and Germany respectively. Companies also save substantially on utilities and land while setting up their operations in India.
The report has done a thorough cost analysis of conducting phase-I, phase-II, phase-III and phase-IV clinical trials in India and abroad and concludes that drug manufacturers and CROs can save anywhere between 50% and 75% by outsourcing their clinical trials to India.
The research says that delay of a single day in completing a clinical trial can cost a company exorbitantly. However, India scores here too as it has a much better track record in patient recruitment and trial completion as compared to many other clinical trial destinations. In fact, companies can cut upto 30% to 40% time required to complete various phases of clinical trials choosing India as the outsourcing destination.
“Booming Clinical Trials Market in India” gives an extensive and objective analysis on the Indian clinical trials market. It investigates the advantages/disadvantages India has in becoming a global clinical trials hub. The report exhaustively evaluates and compares the key factors that drug companies and CROs look before outsourcing clinical trials to a country. These include patient pool, regulatory environment, cost, infrastructure, human resources and past performance in conducting clinical trials.http://www.rncos.com/ |
|
| Keywords |
Booming Clinical Trials Market in India, Indian Clinical Trials Market, Clinical Trials, Clinical Research, Clinical Trials Market, Key Players of Clinical Trials Market, Future of Clinical Trials |
| Category |
Business |
| Submission Date |
Apr 15, 2009 |
| Article Contact Name |
Shushmul Maheshwari || send email to Shushmul Maheshwari
|
|
Other links at Business |
| 1. |
Indonesian Islamic Banks Going Strong
|
|
|
According to a recent research report, “Indonesian Islamic Banking Outlook to 2013” by RNCOS, a leading research firm, with the government support and improving consumer confidence on the Sharia-compliant financial products, the deposits with the system are expected to grow at a strong CAGR of nearly 47% between 2009 and 2013.
The government representative, Central Bank of Indonesia, is following a blueprint for Islamic Banking Development aimed at creating a strong Islamic banking industry by 2015. Under the blueprint, development of the industry will focus on laying strong foundation for prudential provision and supervision; increasing the efficiency of Islamic banking, with the support of a secure and efficient Islamic financial market (to be established by 2009); conforming to international Islamic banking standards; and integrating Islamic banking into the Islamic financial industry. This development strategy, as well as a broader Islamic religious revival in the country that is helping to increase the popularity of Sharia banking products, will lead to continued strong growth in this sector during the forecast period.
The report also found that the financial meltdown has had no negative impact on the development of Sharia banking in the country. While the global gloomy economic environment is raising uncertainties over the global traditional financial system, the Indonesian Sharia banking industry stands to gain from the world economic downturn and anticipates to continue fast growth in the coming years. This optimistic view is based on it very nature (avoid involvement of interest rates) and a robust growth in deposits in the recent months despite financial crisis in world.
“Indonesian Islamic Banking Outlook to 2013” provides a comprehensive research and prudent analysis on the Islamic banking in Indonesia. This extensive research will help the clients to identify the market trends and evaluate the leading-edge opportunities critical to the success of the Islamic banking market in the country. This study gives an overview on the various factors driving the banking industry, together with the forces that are blocking the growth of the industry.
This research supplements the past and current information on the Indonesian Islamic banking market with forecast on various important industry aspects, including Muslim population, disposable income, Sharia financing and deposits.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM180.htm
Check DISCOUNTED REPORTS on http://www.rncos.com
|
| 2. |
US - Potential Export Destination for Low-cost Steel
|
|
|
The US primarily depends on steel imports to fulfill its demand as domestic production remains insufficient to fulfill domestic demand. And according to Our new research report, “US Steel Industry Outlook”, with inventories at low levels at the beginning of the year 2008 and sharp increase in price by domestic mills, the US will remain a hot export destination for low cost economies in near future.
According to the report, the impact of slowing economy is clearly visible on the US steel industry. Crude steel production in the country declined by 0.4% to 98.2 Million Metric Tons whereas crude steel consumption slipped radically by 4.6% reaching an estimated 123 Million Metric Tons in 2007. Though the consumption fall significantly, the production level is still not sufficient to match up the demand. This has further widened the demand-supply gap in the country, making it more reliant on imports to fulfill its domestic demand.
From future perspective, crude steel consumption in the US is forecasted to reach 125 Million Metric Tons in 2009. Steel consumption will be largely driven green & clean energy-related infrastructure because there is huge investment in pipeline in wind, solar and nuclear energy by the US government. In contrast to consumption, its production will only reach 101 Million Metric Tons in the same year. To fill the gap, the country will have to import more steel from other countries.
“US Steel Industry Outlook” contains unique market-based research and provides thorough and prudent analysis on the US steel Industry. It provides extensive statistical and analytical outline on the US Steel industry and gives past, present and future data on its structure, composition and working. The research study intensively discusses the new avenues and challenges that are anticipated to stem both within and from the US steel industry in future.
The research also provides forecast on major industry parameters and help clients in identifying critical opportunities to leverage from.
|
| 3. |
Booming Global Obesity Drug Market
|
|
|
“Booming Global Obesity Drug Market”, our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it’s expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets.
The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi’s Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch.
The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters.
Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China’s obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market.
Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market.
Our report provides forecast on
- Global obesity market
- Xenical revenue
- Meridia revenue
- Alli revenue
- Global prevalence of obesity
- Prevalence of obesity in major developed and emerging markets
Profiling on Key Players
This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM166.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
|
| 4. |
Blackberry phone
|
|
|
Item Specifics - Cell Phones & Smartphones
Carrier: Sprint Nextel Technology: CDMA
Contract: Without Contract Camera: 1-2 Megapixels
Brand: BlackBerry Features: Bluetooth Enabled, Calendar, Color Screen, Email Access, Internet Browser, MMS Enabled, PDA-PC Sync, SMS-Text Messaging, Speakerphone, USB Interface
Model: 8330 CURVE Condition: New, Never Opened
Type: Smartphone (PDA Phone)
SquareTrade © AP6.0
NEW BLACKBERRY CURVE 8330 RED SPRINT CELL PHONE CLEAN ESN 2.0 MP camera, full QWERTY Keyboard, 1GB MicroSD card
Included Accessories:
Standard Li-Ion 1150 mAh
Standard Battery Door
AC Travel Charger
Wired Stereo Headset
1GB MicroSD Card
USB Data Cable
Highlights
Sprint Speed - CDMA/EVDO data speeds
Sprint Software Store with Sprint TV, Sprint Music Store, Sprint Pocket Express, 1 GB microSD Card
Key Features
NASCAR Sprint Cup MobileSM
Sprint Music StoreSM
Sprint TV® enabled
GPS enabled
Slim and fashionable
Web, email capable
Built-in camera
Speakerphone
Bluetooth
External display
Memory card slot
Voice dialing
Broadband speeds where available
2.0 MP camera
5x zoom, enhanced flash, and resolution up to 1600x1200 for Pictures and Videos
Full QWERTY Keyboard and Trackball Navigation
Faster and Easier typing and navigation.
Micro SD Card slot
1GB MicroSD card included give you the room you need for larger work files, presentations, reports, documents or fun files like photos and music.
Media Player
Download and play music, videos, audio files, pictures and ring tones.
BlackBerry push technology for email and messaging
Get all of your email in one place wirelessly. Receive emails from your corporate and personal email accounts.
Organizer
Think fast with an all-encompassing organizer - calendar, contacts, tasks, memos and more right at your fingertips.
Browser
Access the web where and when you need it.
3.5mm Jack
Stereo headset with microphone and mute switch included
GPS
Assisted, autonomous, simultaneous. Supports Sprint Navigation, BlackBerry Maps & other GPS applications.
BlackBerry Maps
View maps and driving directions. Email maps to other BlackBerry users and launch maps from your address book.
NFL Mobile Live access
Listen to live audio broadcasts of every regular season game and watch the live broadcasts of all NFL Network games. Get real-time red zone alerts, scores, stats, live NFL Network 24/7 and more. Manage your fantasy football team like a pro with up-to-the-minute insights, analysis, stats and alerts. How to Access: Text "NFL" to 7777* on your Sprint phone to download a full version of the application or download NFL Mobile Live from Sprint Digital LoungeSM. *Standard text messaging and data rates apply.
Full Messaging Capabilites
Instant Messaging and SMS Text Messaging.
Voice Notes
Make a voice note and send as an email .wmv file attachment.
Voice Command and Voice Activated Dialing
The Built-in speaker independent voice command lets you use your voice to look up contacts, place phone calls and get key information from your device.
Speakerphone
Easy hands free operation.
Mobile Broadband Capable
EVDO Sprint speed for the fastest BlackBerry® Curve™ 8330 smartphone available today.
Bluetooth 2.0 Technology
Fast and secure transmission without cables or wires
|
| 5. |
RNCOS Releases a New Report- Booming Global Obesity Drug Market
|
|
|
RNCOS has recently added a new Market Research Report titled, “Booming Global Obesity Drug Market” to its report gallery. “Booming Global Obesity Drug Market”, our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it’s expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets.
The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi’s Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch.
The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters.
Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China’s obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market.
Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market.
Our report provides forecast on
- Global obesity market
- Xenical revenue
- Meridia revenue
- Alli revenue
- Global prevalence of obesity
- Prevalence of obesity in major developed and emerging markets
Profiling on Key Players
This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM166.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
|
|
|
